Cofoe Medical Technology Co., Ltd. held a new product launch event, unveiling its new dynamic blood glucose monitor, a continuous glucose monitoring system (model CMCC01).
The product centers on an accuracy performance of 6.75% MARD and full-cycle health management services, driving blood glucose management from "single-point monitoring" toward "full-cycle health management."
Liu Bin, General Manager of Cofoe Medical's User Operations Center, stated that users' expectations for such products have never been limited to "just another blood glucose testing tool," but rather two fundamental requirements: accurate measurement, and a wearing experience that is burden-free and can be sustained long-term.
MARD (Mean Absolute Relative Difference) measures the deviation between continuous glucose monitoring (CGM) readings and the clinical gold standard for testing, with smaller values indicating greater accuracy. A value of 6.75% means that within the sample range of this study, the readings were highly consistent with venous blood test results.
The challenge of CGM products lies in the fact that accuracy is not the performance of a single sample, but the consistency across tens of thousands of sensors. "Cramming the four mutually contradictory requirements of miniaturization, long lifespan, calibration-free operation, and biocompatibility simultaneously into an electrode the size of a hair" is how Xu Binjie, Dean of Cofoe's Biosensing and Innovative Materials Research Institute, described it.
The Cofoe dynamic glucose monitor has achieved self-development of its core sensor. Around electrode structure, enzyme membrane formulation, calibration methods, and attenuation compensation, Cofoe has formed 8 core patents. The product completed multi-center, self-controlled clinical research at three Grade 3A hospital research centers. In outpatient home-use scenarios, it achieved a MARD of 6.75%, a 100% Consensus error grid A+B zone rate, a 100.0% sensor normal operation rate over 14 days, with no serious adverse events or device defects.
The Cofoe dynamic glucose monitor features an integrated design that allows users to self-apply it with a twist, a press, and a push. By scanning a QR code through the Cofoe Health App, users connect instantly. A single wear lasts up to 14 days, with data updated every 5 minutes. High and low blood glucose alerts can be set, and data supports remote sharing with family members. With IP28 protection and low-sensitivity medical adhesive patches, there is no need to remove the device during showering or swimming. Additionally, the new product achieves ecosystem integration with Leqi AI glasses, allowing real-time blood glucose and trend changes to be seen with a glance. In 2026, Cofoe will also become the first home health medical device industry partner to integrate into the OpenHarmony ecosystem. Blood pressure monitors, blood glucose meters, and thermometers already support instant connection upon HarmonyOS phone startup, and in the future, the Cofoe Health App will also release a native HarmonyOS version, bringing users more cross-ecosystem experiences.
Comments